Illumina, MyOme announces collaboration, investment by Illumina into MyOme

Illumina (ILMN) and MyOme announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance MyOme’s strategic roadmap including MyOme’s Proactive Health, MPH, Trial – a large-scale prospective trial that aims to prove enhanced patient outcomes and substantial cost savings resulting from use of whole-genome sequencing, WGS, combined with MyOme’s AI-integrated risk models, IRMs, for common, chronic conditions, cancers, and rare disease. The collaboration will also support MyOme’s ability to expand its commercially available products, including a suite of proactive health and rare disease diagnostic tests